Evidence map›Paper›PMID 41247261›Full record

ArticleInfluenza and other respiratory viruses2025

Incidence Rates of RSV-Associated Hospitalizations Among Adults in Middle Tennessee, United States, October 2022 Through September 2023.

Carlos G Grijalva, Jesse O Wrenn, Jonathan E Schmitz, Karen F Miller, Adrienne Baughman, Ian D Jones, James D Chappell, Natasha B Halasa, Paul W Blair, Yuwei Zhu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Carlos G GrijalvaVanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-2329-7797
Jesse O WrennVanderbilt University Medical Center, Nashville, Tennessee, USA.
Jonathan E SchmitzVanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-2727-9078
Karen F MillerVanderbilt University Medical Center, Nashville, Tennessee, USA.
Adrienne BaughmanVanderbilt University Medical Center, Nashville, Tennessee, USA.
Ian D JonesVanderbilt University Medical Center, Nashville, Tennessee, USA.
James D ChappellVanderbilt University Medical Center, Nashville, Tennessee, USA.
Natasha B HalasaVanderbilt University Medical Center, Nashville, Tennessee, USA.
Paul W BlairVanderbilt University Medical Center, Nashville, Tennessee, USA.
Yuwei ZhuVanderbilt University Medical Center, Nashville, Tennessee, USA.
H Keipp TalbotVanderbilt University Medical Center, Nashville, Tennessee, USA.
Jonathan D CaseyVanderbilt University Medical Center, Nashville, Tennessee, USA.
Fatimah S DawoodCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Diya SurieCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Wesley H SelfVanderbilt University Medical Center, Nashville, Tennessee, USA.
Investigating Respiratory Viruses in the Acutely Ill (IVY) Network

Funding

Vanderbilt Interdisciplinary Hospital-Based Systems of Care Research and Training ProgrAm (VISTA)T32HL170986 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SUNIL KRIPALANI, ALAN B STORROW · 2024 to 2026
$1.3M
NHLBI NIH HHS T32 HL170986Vanderbilt University Medical Center and the United States Centers Disease Control and Prevention 75D30122C14944
6 · The paper itself

Abstract

We estimated the burden of RSV-associated hospitalizations in US adults 1 year prior to RSV vaccine introduction. The overall annual incidence rate of RSV-associated hospitalization was 31.47 (95% CI: 21.89-43.97) per 100,000 adults. Rates were 10-fold and 17-fold higher among adults 60 to 74 years and ≥ 75 years compared with adults 18 to 49 years old. This prospective assessment demonstrated the burden of RSV-associated hospitalizations among adults, with the highest hospitalization rates among adults ≥ 60 years old, in the year prior to RSV vaccine introduction.

Indexed as

HospitalizationRespiratory Syncytial Virus InfectionsAdolescentAdultAgedFemaleHumansIncidenceMaleMiddle AgedProspective StudiesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus VaccinesTennesseeYoung AdultRespiratory Syncytial Virus Vaccinesadultshospitalizationratesrespiratory syncytial virus

Identifiers

PMID41247261
PMCPMC12378065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.